mTOR Inhibitors
- Name
- mTOR Inhibitors
- Accession Number
- DBCAT004158
- Description
Medications that exert their immunosuppressive effects via inhibition of the mammalian target of rapamycin (mTOR)
- Drugs
Drug Drug Description AZD-8055 AZD8055 has been used in trials studying the treatment of Cancer, Lymphomas, Solid Tumors, MALIGNANT GLIOMA, and brainstem glioma, among others. Everolimus A mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies. Gedatolisib A pan-PI3K and mTORC1/2 inhibitor used as part of a second-line chemotherapy regimen for HR-positive, HER2-negative advanced breast cancer without a PIK3CA mutation following endocrine therapy. GSK-1059615 GSK1059615 has been used in trials studying the treatment of Lymphoma, Solid Tumours, Endometrial Cancer, Solid Tumor Cancer, and Metastatic Breast Cancer. OSI-027 OSI-027 has been used in trials studying the treatment of Any Solid Tumor or Lymphoma. Pimecrolimus A topical calcineurin inhibitor used in the treatment of mild-moderate atopic dermatitis who are not candidates for other types of therapy due to previous lack of response or other reasons. Ridaforolimus Investigated for use/treatment in solid tumors, sarcoma, cancer/tumors (unspecified), endometrial cancer, prostate cancer, and bone metastases. Sirolimus An mTOR inhibitor immunosuppressant used to prevent organ transplant rejections, treat lymphangioleiomyomatosis, and treat adults with perivascular epithelioid cell tumors. Temsirolimus A antineoplastic agent used in the treatment of renal cell carcinoma (RCC) that works by inhibiting mTOR. Vistusertib Vistusertib is under investigation for the treatment of Advanced Gastric Adenocarcinoma. - Drugs & Drug Targets